Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers

Young J. Lee, Philomena Doliny, Carmen Gomez-Fernandez, Jodeen Powell, Isildinha Reis, Judith Hurley

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

A phase II trial was designed to evaluate the effectiveness of docetaxel/cisplatin as primary or neoadjuvant chemotherapy of locally advanced breast carcinoma (LABC). Patients with newly diagnosed breast cancers ≥ 5 cm in size by palpation were treated with docetaxel/cisplatin, both at 70 mg/m2 intravenously every 21 days for 4 courses. Upon completion of chemotherapy, all patients underwent modified radical mastectomy with axillary nodal dissection. Pathologic complete response (pCR) was defined as absence of any invasive carcinoma in the breast. Standard AC (doxorubicin/cyclophosphamide) at 60 mg/m2 and 600 mg/m2, respectively, for 4 cycles was given as adjuvant therapy to maximally eradicate occult distant disease. Between March 1998 and October 2001, 57 women were entered onto this trial, 28 (49%) with inoperable T4 and inflammatory cancers. Pretreatment median tumor size was 9 cm. Thirty-six patients (63%) had estrogen receptor-positive tumors and 10 patients (18%) had tumors with HER2 overexpression. All tumors became operable after neoadjuvant chemotherapy. Pathologic complete response in the breast was achieved in 15 patients (26%) and pCR in the breast and the axilla was achieved in 11 patients (20%). All neoadjuvant chemotherapy courses were administered at full doses without treatment delays caused by toxicity. The most common side effects were hyperglycemia, anemia, and mild neuropathy. The results of this study suggest that the docetaxel/cisplatin combination can be an effective and well-tolerated induction treatment of LABC, even in very large mostly HER2-nonoverexpressing tumors.

Original languageEnglish (US)
Pages (from-to)371-376
Number of pages6
JournalClinical breast cancer
Volume5
Issue number5
DOIs
StatePublished - Dec 2004

    Fingerprint

Keywords

  • Complete pathologic response
  • Inflammatory breast cancer
  • Neoadjuvant chemotherapy
  • Platinum agents
  • Surrogate marker

ASJC Scopus subject areas

  • Cancer Research

Cite this